Header Logo

Connection

Andrew Ambrosy to Hospitalization

Back to Details
This is a "connection" page, showing publications Andrew Ambrosy has written about Hospitalization.
Andrew Ambrosy
Connection Strength
5.479
Hospitalization
  1. A Natural Language Processing-Based Approach for Identifying Hospitalizations for Worsening Heart Failure Within an Integrated Health Care Delivery System. JAMA Netw Open. 2021 11 01; 4(11):e2135152.
    View in: PubMed
    Score: 0.529
  2. Prevalent digoxin use and subsequent risk of death or hospitalization in ambulatory heart failure patients with a reduced ejection fraction-Findings from the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) randomized controlled trial. Am Heart J. 2018 05; 199:97-104.
    View in: PubMed
    Score: 0.409
  3. Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes: Findings From the ASCEND-HF Trial. JACC Heart Fail. 2017 01; 5(1):1-13.
    View in: PubMed
    Score: 0.378
  4. Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST Trial. Circ Heart Fail. 2016 05; 9(5).
    View in: PubMed
    Score: 0.361
  5. The use of digoxin in patients with worsening chronic heart failure: reconsidering an old drug to reduce hospital admissions. J Am Coll Cardiol. 2014 May 13; 63(18):1823-32.
    View in: PubMed
    Score: 0.311
  6. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol. 2014 Apr 01; 63(12):1123-1133.
    View in: PubMed
    Score: 0.309
  7. Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. Eur Heart J. 2013 Mar; 34(11):835-43.
    View in: PubMed
    Score: 0.287
  8. The role of marijuana use disorder in predicting emergency department and inpatient encounters: A retrospective cohort study. Drug Alcohol Depend. 2017 09 01; 178:170-175.
    View in: PubMed
    Score: 0.195
  9. Effect of Medically Tailored Meals on Clinical Outcomes in Recently Hospitalized High-Risk Adults. Med Care. 2022 10 01; 60(10):750-758.
    View in: PubMed
    Score: 0.140
  10. Analysis of Worsening Heart Failure Events in an Integrated Health Care System. J Am Coll Cardiol. 2022 Jul 12; 80(2):111-122.
    View in: PubMed
    Score: 0.139
  11. Trends and characteristics of hospitalizations for heart failure in the United States from 2004 to 2018. ESC Heart Fail. 2022 04; 9(2):947-952.
    View in: PubMed
    Score: 0.134
  12. Hospitalizations for heart failure and mortality risk during the evolving coronavirus disease 2019 pandemic - the wave may break but a dangerous undertow persists. Eur J Heart Fail. 2020 12; 22(12):2225-2227.
    View in: PubMed
    Score: 0.124
  13. Hospitalizations for heart failure during the COVID-19 pandemic: making sense of the known knowns, known unknowns, and unknown unknowns. Eur J Heart Fail. 2020 10; 22(10):1752-1754.
    View in: PubMed
    Score: 0.121
  14. Hyperglycemia and outcomes in acute heart failure - A bittersweet relationship. Int J Cardiol. 2020 02 01; 300:196-197.
    View in: PubMed
    Score: 0.115
  15. Applying data science approaches to identify frequent flyers in heart failure: rise of the machines. Eur J Heart Fail. 2019 03; 21(3):319-321.
    View in: PubMed
    Score: 0.109
  16. Relationship between timing of trial randomization, protocol completion, and clinical outcomes among patients hospitalized for heart failure: from the ASTRONAUT trial. Eur J Heart Fail. 2018 12; 20(12):1760-1763.
    View in: PubMed
    Score: 0.108
  17. Sudden cardiac death following admission for acute heart failure: adding insult to injury. Eur J Heart Fail. 2018 03; 20(3):533-535.
    View in: PubMed
    Score: 0.101
  18. Lessons learned in acute heart failure. Eur J Heart Fail. 2018 04; 20(4):630-641.
    View in: PubMed
    Score: 0.100
  19. Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure: From the ASCEND-HF Trial. J Am Coll Cardiol. 2017 Jun 27; 69(25):3029-3039.
    View in: PubMed
    Score: 0.098
  20. Trajectory of Congestion Metrics by Ejection Fraction in Patients With Acute Heart Failure (from the Heart Failure Network). Am J Cardiol. 2017 07 01; 120(1):98-105.
    View in: PubMed
    Score: 0.096
  21. Reply: Factors That May Affect Body Change During and After Hospitalization for Acute Heart Failure. JACC Heart Fail. 2017 04; 5(4):311-312.
    View in: PubMed
    Score: 0.096
  22. The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF. Eur J Heart Fail. 2016 Mar; 18(3):306-13.
    View in: PubMed
    Score: 0.087
  23. Hospitalized Heart Failure in the United States: Lessons Learned from Clinical Trial Populations. Heart Fail Clin. 2015 Oct; 11(4):591-601.
    View in: PubMed
    Score: 0.086
  24. Global perspectives in hospitalized heart failure: regional and ethnic variation in patient characteristics, management, and outcomes. Curr Heart Fail Rep. 2014 Dec; 11(4):416-27.
    View in: PubMed
    Score: 0.082
  25. Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure. Heart Fail Rev. 2013 Mar; 18(2):107-22.
    View in: PubMed
    Score: 0.072
  26. Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial. Eur J Heart Fail. 2013 Jan; 15(1):61-8.
    View in: PubMed
    Score: 0.070
  27. The impact of chronic obstructive pulmonary disease in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST Trial. J Card Fail. 2012 Jul; 18(7):515-23.
    View in: PubMed
    Score: 0.069
  28. Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST trial. Eur J Heart Fail. 2012 Mar; 14(3):302-11.
    View in: PubMed
    Score: 0.068
  29. Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. Eur Heart J. 2011 Oct; 32(20):2563-72.
    View in: PubMed
    Score: 0.065
  30. Characteristics and Outcomes of Suspected Digoxin Toxicity and Immune Fab Treatment Over the Past Two Decades-2000-2020. Am J Cardiol. 2022 11 15; 183:129-136.
    View in: PubMed
    Score: 0.035
  31. Temporal trends in the outcomes of acute heart failure: between consolatory evidences and real progress. Eur J Heart Fail. 2021 03; 23(3):432-435.
    View in: PubMed
    Score: 0.032
  32. Loop Diuretic Use and Outcomes in Chronic Stable Heart Failure With Preserved Ejection Fraction-Reply. Mayo Clin Proc. 2021 02; 96(2):503-506.
    View in: PubMed
    Score: 0.031
  33. The Degree of the Predischarge Pulmonary Congestion in Patients Hospitalized for Worsening Heart Failure Predicts Readmission and Mortality. Cardiology. 2021; 146(1):49-59.
    View in: PubMed
    Score: 0.031
  34. Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial. JACC Heart Fail. 2020 10; 8(10):789-799.
    View in: PubMed
    Score: 0.030
  35. The Covid-19 Pandemic and the Incidence of Acute Myocardial Infarction. N Engl J Med. 2020 08 13; 383(7):691-693.
    View in: PubMed
    Score: 0.030
  36. Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction: Insights From the FIGHT Trial. Circ Heart Fail. 2020 05; 13(5):e006758.
    View in: PubMed
    Score: 0.030
  37. The burden of non-cardiac comorbidities and association with clinical outcomes in an acute heart failure trial - insights from ASCEND-HF. Eur J Heart Fail. 2020 06; 22(6):1022-1031.
    View in: PubMed
    Score: 0.030
  38. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial. JAMA Cardiol. 2020 02 01; 5(2):202-207.
    View in: PubMed
    Score: 0.029
  39. Haemoconcentration during treatment of acute heart failure with cardiorenal syndrome: from the CARRESS-HF trial. Eur J Heart Fail. 2019 11; 21(11):1472-1476.
    View in: PubMed
    Score: 0.028
  40. Expanded algorithm for managing patients with acute decompensated heart failure. Heart Fail Rev. 2018 07; 23(4):597-607.
    View in: PubMed
    Score: 0.026
  41. Improving Postdischarge Outcomes in Acute Heart Failure. Am J Ther. 2018 Jul/Aug; 25(4):e475-e486.
    View in: PubMed
    Score: 0.026
  42. Influence of atrial fibrillation on post-discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the ASTRONAUT trial. Eur J Heart Fail. 2017 04; 19(4):552-562.
    View in: PubMed
    Score: 0.023
  43. In-Hospital Diuretic Agent Use and Post-Discharge Clinical Outcomes in Patients Hospitalized for Worsening Heart Failure: Insights From the EVEREST Trial. JACC Heart Fail. 2016 07; 4(7):580-588.
    View in: PubMed
    Score: 0.022
  44. Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure. Am J Cardiol. 2016 Apr 01; 117(7):1144-50.
    View in: PubMed
    Score: 0.022
  45. Length of hospital stay and 30-day readmission following heart failure hospitalization: insights from the EVEREST trial. Eur J Heart Fail. 2015 Oct; 17(10):1022-31.
    View in: PubMed
    Score: 0.021
  46. Patterns of intensive care unit admissions in patients hospitalized for heart failure: insights from the RO-AHFS registry. J Cardiovasc Med (Hagerstown). 2015 May; 16(5):331-40.
    View in: PubMed
    Score: 0.021
  47. International REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure (REPORT-HF): rationale for and design of a global registry. Eur J Heart Fail. 2015 May; 17(5):527-33.
    View in: PubMed
    Score: 0.021
  48. Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial). Am J Cardiol. 2014 Dec 01; 114(11):1713-21.
    View in: PubMed
    Score: 0.020
  49. Designing effective drug and device development programs for hospitalized heart failure: a proposal for pretrial registries. Am Heart J. 2014 Aug; 168(2):142-9.
    View in: PubMed
    Score: 0.020
  50. Relation of serum magnesium levels and postdischarge outcomes in patients hospitalized for heart failure (from the EVEREST Trial). Am J Cardiol. 2013 Dec 01; 112(11):1763-9.
    View in: PubMed
    Score: 0.019
  51. Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Eur J Heart Fail. 2013 Dec; 15(12):1401-11.
    View in: PubMed
    Score: 0.019
  52. Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial. J Am Coll Cardiol. 2013 Feb 05; 61(5):571-9.
    View in: PubMed
    Score: 0.018
  53. Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: findings from the EVEREST Trial. Am Heart J. 2012 Dec; 164(6):884-92.e2.
    View in: PubMed
    Score: 0.018
  54. A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial. Heart Fail Rev. 2012 May; 17(3):485-509.
    View in: PubMed
    Score: 0.017

© 2024 Kaiser Permanente